Menu Search
Equities

Hepion Pharmaceuticals Inc

336:BER

Hepion Pharmaceuticals Inc

Actions
  • Price (EUR)0.00
  • Today's Change0.00 / --
  • Shares traded-1.00
  • 1 Year change-100.00%
  • Beta--
Data delayed at least 15 minutes, as of Jun 05 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of drug therapy for treatment of chronic liver diseases. The Company is developing a treatment for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), and other chronic liver diseases. Its cyclophilin inhibitor, rencofilstat, is being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease. It is developing rencofilstat as its lead molecule. Rencofilstat is a compound that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulate protein folding, in addition to other activities. It has developed and maintains an artificial intelligence deep machine learning (AI/ML) platform designed to understand disease processes and identify patients that are rencofilstat responders. In addition, its AI/ML can be used to further NASH and HCC clinical development programs.

  • Revenue in USD (TTM)0.00
  • Net income in USD-48.93m
  • Incorporated2013
  • Employees22.00
  • Location
    Hepion Pharmaceuticals Inc399 Thornall StEDISON 08837-2236United StatesUSA
  • Phone+1 (732) 902-4000
  • Fax+1 (732) 902-4100
  • Websitehttps://hepionpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.